Skip to main content
BIOVF logo

Swedish Orphan Biovitrum AB (BIOVF) Stock Price & Analysis

Swedish Orphan Biovitrum AB (BIOVF) — price $51.05 (0.00%), as of the Nov 19, 2026 trading session; market cap $17.8B. Expected results Oct 27, 2026.

Educational signal · not a buy or sell recommendation · How to read this

$51.05 $0.00 (0.00%) Market Cap $17.8B

Swedish Orphan Biovitrum AB · BIOVF · Healthcare · Medical - Pharmaceuticals

Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ONC · BeOne Medicines Ltd. · 96 /100
  • DMRA · Galecto, Inc. · 50 /100
  • CGEM · Cullinan Therapeutics, Inc. · 51 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$51.05
Change on the day0.00%
52-week range$29.18–$51.05
Market capitalisation$17.8B
Price / earnings (trailing)24.72
Shares traded on the day100
Beta (volatility vs the S&P 500)0.29

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Aug 15, 2025 to Nov 19, 2026: low $29, high $51, latest $51. 3 reported quarters marked, 2 above and 1 below the recorded estimate. 1 other dated event marked. $51 $29 high $51 Feb 5, 2026 · Earnings results · reported above the recorded estimate · close $371Apr 28, 2026 · Earnings results · reported above the recorded estimate · close $472Jul 16, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $493Jul 16, 2026 · Earnings results · reported below the recorded estimate · close $494 Aug 15, 2025 Nov 19, 2026 · $51 $29Aug 15, 2025$31Aug 29, 2025$29Sep 12, 2025$30Sep 26, 2025$33Oct 10, 2025$33Oct 24, 2025$35Nov 7, 2025$35Nov 21, 2025$35Dec 5, 2025$35Dec 19, 2025$35Jan 2, 2026$37Jan 16, 2026$37Jan 30, 2026$37Feb 13, 2026$37Feb 27, 2026$41Mar 13, 2026$41Mar 27, 2026$40Apr 10, 2026$40Apr 24, 2026$47May 8, 2026$47May 22, 2026$48Jun 5, 2026$48Jun 18, 2026$48Jul 2, 2026$49Jul 17, 2026$48Jul 31, 2026$48Aug 14, 2026$48Aug 28, 2026$48Sep 11, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Management outlook

As of

  • Now to add some color to this guidance upgrade related to revenue, we saw 26% growth at CER in H1, and we expect momentum to continue with ALTUVOCT, Doptelet, and Gamifant being the main growth drivers in full year 2026.

    Henrik Stenqvist · Statement from

  • We will also have increased costs for the launch of Aspaveli nephrology as we continue the rollout in Europe, as well as in Tryngolza, where we will ensure a strong and well-prepared market entry to address the larger patient opportunity in sHTG, which we expect to launch next year.

    Henrik Stenqvist · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations can change.

Source records

Other perspectives

Council score for Swedish Orphan Biovitrum AB (BIOVF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Neutral
ROE Weak
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Swedish Orphan Biovitrum AB (BIOVF), and what does it report?

Short answer · as of

Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Healthcare / Medical Pharmaceuticals Headquarters: Norra Stationsgatan 93A, Stockholm, 112 76, SE. It employs 1,888 people and is led by Guido Oelkers. In Q3 FY2026 it reported revenue of kr8.63B and net income of kr2.22B. The market values it at $17.8B.

2 · Latest results

What do the latest results show for Swedish Orphan Biovitrum AB (BIOVF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of kr8.63B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$805.37M Jul 16, 2026
Latest report · revenue estimate
$752.41M Jul 16, 2026
Latest report · revenue vs estimate
Above estimate Jul 16, 2026
Latest report · EPS vs estimate
Below estimate Jul 16, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Jul 16, 2026$805.37M$752.41M$0.3288$0.3800
Apr 28, 2026$755.76M$749.76M$0.4500$0.3821
Feb 5, 2026$846.23M$863.40M$0.6000$0.4567
Oct 20, 2025$823.48M$818.85M−$0.8811$0.4925
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026kr8.63Bkr2.22Bkr6.37 (diluted)
Q2 FY2026kr7.84Bkr1.10Bkr3.14 (diluted)
Q1 FY2026kr7.18Bkr1.32Bkr3.77 (diluted)
Q4 FY2025kr7.80Bkr1.86Bkr5.33 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Swedish Orphan Biovitrum AB (BIOVF)?

Short answer · as of

The distress and quality screens read Altman Z 3.85 · Piotroski F 7. Trailing ratios: ROE 16.0% · ROA 7.8% · current ratio 0.99 · earnings yield 3.9% · free-cash-flow yield 4.3%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BIOVF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BIOVF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Swedish Orphan Biovitrum AB (BIOVF)?

Read these with our analysis →

BIOVF Healthcare Stock FAQ

These answers are editorial: 1 of these 8 answers is drawn from the BIOVF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is BIOVF a good stock to buy?

Stock Expert AI does not rate BIOVF buy, sell or hold. Swedish Orphan Biovitrum AB has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the BIOVF stock price today?

The last price recorded for Swedish Orphan Biovitrum AB (BIOVF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the implications of BIOVF trading on the OTC market?

Trading on the OTC market, specifically the 'OTC Other' tier, carries several implications for BIOVF investors. This tier typically has less stringent listing and disclosure requirements compared to major exchanges like the NYSE or NASDAQ, which can lead to reduced transparency regarding financial reporting and corporate governance.

What are the key factors to evaluate for BIOVF?

Evaluate BIOVF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does BIOVF data refresh on this page?

BIOVF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven BIOVF's recent stock price performance?

Swedish Orphan Biovitrum AB (BIOVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established portfolio of specialized drugs for rare diseases in hematology, immunology, and genetic/metabolic conditions. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BIOVF overvalued or undervalued right now?

The trailing P/E of Swedish Orphan Biovitrum AB (BIOVF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research BIOVF before investing?

Before investing in Swedish Orphan Biovitrum AB (BIOVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 39 figures on this page — 1 from SEC filings and earnings calls, 33 from Financial Modeling Prep (FMP), 3 with no recorded source and 2 computed by us, formula shown in the register. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.